🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Malignant Solid Neoplasm

Access to Genetic Testing in Underserved Patients With Cancer NCT06422455NA2 sites📍 Los Angeles📍 Rochester University of Southern California · Tests: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048Phase 11 site📍 Hangzhou Weijia Fang, MD · Tests: Intraperitoneal infusion of FAST CEA-targeted CAR-T A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018Phase 1, Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 NK Cell Therapy for Malignant Solid Brain Tumors NCT07552233NA4 sites📍 Beijing📍 Qinhuangdao📍 Zhengzhou Peking University Third Hospital · Tests: Autologous NK cells A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. NCT04116541Phase 213 sites📍 Angers📍 Bordeaux📍 Caen Centre Leon Berard · Tests: HDM201, Ribociclib, Cabozantinib, Alectinib, Regorafenib AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors NCT05372640Phase 17 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing Collection and Storage of Tissue and Blood Samples From Patients With Cancer NCT02474160n/a140 sites📍 Birmingham📍 Fort Smith📍 Arroyo Grande National Cancer Institute LAO · Tests: Cytology Specimen Collection Procedure Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110Phase 115 sites📍 Phoenix📍 San Diego📍 Tampa MOMA Therapeutics · Tests: MOMA-341, Irinotecan, Immunotherapy Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors NCT04684459EARLY Phase 11 site📍 Chengdu Sichuan University · Tests: Dual-targeting HER2 and PD-L1 CAR-T cells Imaging of Solid Tumors Using 18F-TRX NCT06942104Phase 11 site📍 San Francisco Rahul Aggarwal · Tests: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 NCT06240728Phase 18 sites📍 Baltimore📍 Boston📍 The Bronx NextPoint Therapeutics, Inc. · Tests: NPX887 Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer NCT07664579n/a1 site📍 Duarte City of Hope Medical Center · Tests: Non-Interventional Study A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites📍 Los Angeles📍 Sarasota📍 St Louis Angiex, Inc. · Tests: AGX101 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270Phase 12 sites📍 Zhengzhou📍 Shanghai Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Tests: SYN818 A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) NCT06521554Phase 121 sites📍 Irvine📍 Sacramento📍 Stanford Nuvalent Inc. · Tests: NVL-330 Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers NCT07540650Phase 21 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: Prophylactic External Beam Radiotherapy, Standard of Care A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors NCT07105215Phase 1, Phase 239 sites📍 Beijing📍 Fuzhou📍 Fuzhou RemeGen Co., Ltd. · Tests: RC278 A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) NCT05118789Phase 1, Phase 263 sites📍 Orange📍 Palo Alto📍 Sacramento Nuvalent Inc. · Tests: Zidesamtinib (NVL-520) First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors NCT05875168Phase 1, Phase 261 sites📍 Sarasota📍 Sarasota📍 Locust Grove Daiichi Sankyo · Tests: DS-3939a A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497Phase 1, Phase 215 sites📍 Los Angeles📍 Rancho Santa Margarita📍 Weston Krystal Biotech, Inc. · Tests: KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors NCT06108050Phase 110 sites📍 Encinitas📍 Fresno📍 Denver Jazz Pharmaceuticals · Tests: JZP898, Pembrolizumab Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. NCT07483658NA4 sites📍 Gatineau📍 Montreal📍 Montreal CHU de Quebec-Universite Laval · Tests: Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radi… A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors NCT07537881Phase 1, Phase 214 sites📍 Hunan📍 Sichuan📍 Fujian RemeGen Co., Ltd. · Tests: RC288 For Injection, RC288 For Injection Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery NCT03184038NA2 sites📍 Sewell📍 Philadelphia Sidney Kimmel Comprehensive Cancer Center at Thomas Jeffers… · Tests: Cognitive Assessment, Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy, Quality-of-Life Assessment MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors NCT06912152Phase 11 site📍 Hangzhou Zhejiang University · Tests: MT027 CAR-T cells Study of MHB088C for Patients With Advanced Solid Malignant Tumors NCT07102004Phase 1, Phase 21 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: MHB088C for Injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy